Evofem Biosciences, Inc. EVFM
We take great care to ensure that the data presented and summarized in this overview for Evofem Biosciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in EVFM
Top Purchases
Top Sells
About EVFM
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Insider Transactions at EVFM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 12
2024
|
Yan Zhang CFO |
SELL
Open market or private sale
|
Direct |
104
-100.0%
|
$0
$0.04 P/Share
|
|
Dec 21
2023
|
Kim P. Kamdar Director |
SELL
Open market or private sale
|
Direct |
10
-100.0%
|
$0
$0.62 P/Share
|
|
Dec 31
2022
|
Saundra L Pelletier Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
50,000
-21.12%
|
-
|
|
May 27
2022
|
Saundra L Pelletier Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
141,000
+37.33%
|
$0
$0.35 P/Share
|
|
Feb 18
2022
|
Saundra L Pelletier Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
750,000
+34.31%
|
-
|
|
Feb 18
2022
|
Justin J. File Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
450,000
+35.69%
|
-
|
|
Feb 18
2022
|
Alexander A Fitzpatrick General Counsel and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
300,000
+36.75%
|
-
|
|
Dec 31
2021
|
Saundra L Pelletier Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
300,000
-30.43%
|
-
|
|
Dec 31
2021
|
Justin J. File Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
120,000
-24.95%
|
-
|
|
Dec 31
2021
|
Alexander A Fitzpatrick General Counsel and Secretary |
SELL
Sale (or disposition) back to the issuer
|
Direct |
120,000
-35.67%
|
-
|
|
Dec 20
2021
|
Saundra L Pelletier Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
135,000
+12.04%
|
$0
$0.38 P/Share
|
|
Dec 20
2021
|
Justin J. File Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
40,594
+7.78%
|
$0
$0.37 P/Share
|
|
Dec 20
2021
|
Alexander A Fitzpatrick General Counsel and Secretary |
BUY
Open market or private purchase
|
Direct |
25,000
+6.92%
|
$0
$0.39 P/Share
|
|
Jul 08
2021
|
Russell Barrans Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
19,998
-4.27%
|
$0
$0.98 P/Share
|
|
Jun 18
2021
|
Kim P. Kamdar Director |
BUY
Open market or private purchase
|
Direct |
10,000
+34.14%
|
$10,000
$1.17 P/Share
|
|
Jun 14
2021
|
Anthony Stephen O'Brien Director |
BUY
Open market or private purchase
|
Direct |
8,140
+50.0%
|
$8,140
$1.31 P/Share
|
|
Jun 11
2021
|
Lisa Dale Rarick Director |
BUY
Open market or private purchase
|
Direct |
5,000
+32.79%
|
$5,000
$1.2 P/Share
|
|
Jun 11
2021
|
Russell Barrans Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
18,180
+3.74%
|
$18,180
$1.14 P/Share
|
|
Jun 10
2021
|
Alexander A Fitzpatrick General Counsel and Secretary |
BUY
Open market or private purchase
|
Direct |
10,000
+3.11%
|
$10,000
$1.02 P/Share
|
|
Jun 10
2021
|
Saundra L Pelletier Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
50,000
+5.55%
|
$50,000
$1.03 P/Share
|
Last 12 Months Summary
| Open market or private sale | 114 shares |
|---|